Table of Contents
The diabetes field continues to innovate, and it looks like 2024 will be another exciting year.
At the end of 2023, we compiled a list of the year’s 10 biggest diabetes technology stories. However, some of these stories won’t end in his 2023, with some major product launches on the horizon.
New CGMs, insulin pumps, and combinations of the two are all expected to hit the market in the coming months. Here are some of the most anticipated products scheduled to launch in the diabetes space in 2024, as well as some of the technologies that have already launched.
Diabetes is on the horizon
Medtronic’s new pump and sensor combination
In January, Medtronic received the CE mark for the MiniMed 780G automated insulin administration system with Simplera Sync sensor.
Simplera Sync is a disposable, all-in-one continuous glucose monitor (CGM) that eliminates finger pricks and retaping. A simple two-step insertion process provides an improved user experience at half the size of previous Medtronic sensors.
The MiniMed 780G, an automatic insulin dosing system, offers meal detection technology to automatically adjust and correct blood sugar levels every 5 minutes. This occurs for both basal (background) and bolus (meal) insulin needs. The system, in conjunction with Guardian 4 sensors, is already commercially available in regions including the United States and Europe.
Medtronic plans to make the MiniMed 780G with Simplera Sync available in Europe through a limited release in Spring 2024. A phased commercial launch is then planned for the summer of 2024. Although still in the research phase in the United States, the combination could be released there if approved. I’ll be there soon.
The company also began rolling out its smart insulin pen system, InPen, powered by Simplera in Europe late last year.
Dexcom’s 15-day CGM for non-insulin users
Almost a year ago, Dexcom announced the next generation G7 CGM. Now, the company is gearing up for its next major product launch.
Dexcom announced in January that it had submitted its new sensor, Stelo, to the FDA for review. The company plans to launch Stelo, designed for type 2 diabetics who don’t use insulin, this summer. San Diego-based Dexcom designed his 15-day wearable Stelo with a cash payment option. It features a software experience specifically tailored for non-insulin users.
At its Investor Day event in June, the company revealed plans to launch new products in the U.S. in 2024. Dexcom says the target audience includes about 70% of Americans with diabetes.
The device can be worn for 15 days and also comes with a cash payment option. Provides a software experience specifically tailored for non-insulin users. Dexcom CEO Kevin Sayer said the device won’t “burden” users with alerts or alarms for insulin users. Drug delivery business news Shortly after the company filed with the FDA. Rather, it just provides the insights the user wants.
Stelo exists on the current G7 platform, so manufacturing is already happening on the company’s current lines, Thayer said. He also believes the company needs to create product classes for targeted audiences with long-term reimbursement for devices.
The company plans to launch Stelo in the US in summer 2024.
Insulet’s new pump
Already a leader in the insulin patch pump market with its Omnipod devices (its latest product is the Omnipod 5), Insulet has found a way to further expand its audience.
In April 2023, the company received FDA approval for its long-acting insulin delivery device Omnipod GO.
Omnipod GO is cleared for patients with type 2 diabetes over the age of 18 and covers patients on basal insulin only. Eligible people usually receive daily injections of long-acting insulin.
This first-of-its-kind, stand-alone wearable insulin delivery system delivers sustained rapid-acting insulin at a constant rate over 72 hours. It features tubeless, waterproof pods and comes in seven different pre-programmed daily rates. These rates range from 10 to 40 units per day.
Insulet said it developed the product to serve patients with type 2 diabetes who are in the early stages of treatment. The technology launches pod therapy, built on Insulet’s long-standing Omnipod platform and enables insulin delivery rather than daily injections. If a patient becomes insulin intensive, Insulet provides a seamless transition to another Omnipod product that fits the patient’s needs.
The company plans to release it in 2024.
These diabetes products have already started rolling out this year
tandem mobi
In February, Tandem Diabetes Care announced the commercial launch of its Mobi insulin patch pump in the United States.
The San Diego-based company says Mobi, which is fully controllable from a mobile app, is the world’s smallest durable automated insulin dosing (AID) system. It received FDA approval in July 2023 for diabetic patients aged 6 years and older.
The Mobi features a 200-unit insulin cartridge and an on-pump button, providing an alternative to phone control for insulin bolus administration. Achieved at less than half the size of existing tandem pump systems. t:Slim X2 pump. Mobi can fit into your coin pocket, clip onto your clothing, or attach to your body with an adhesive sleeve.
This system features the same Control-IQ technology as the acclaimed t:slim X2. Control-IQ is an advanced hybrid closed-loop automated insulin delivery feature that predicts and prevents hyperglycemia and hypoglycemia. This leads to improved cruising range throughout the day and night.
Dexcom ONE+
In Europe, Dexcom offers the G6 CGM platform through a differentiated product called Dexcom ONE.
Earlier this year, the company launched the next version of the product, Dexcom ONE+, in Europe. The company began rolling out the system in Spain, Belgium and Poland in February, followed by the Netherlands a week later. In some countries, this system replaces the previous generation of his Dexcom One sensors.
ONE+ uses Dexcom’s established sensor design, which the company built with feedback from users and medical professionals. The company says this ensures an easy-to-use and highly effective CGM experience for people who treat type 1 or type 2 diabetes with insulin.
This version of the platform utilizes the latest generation G7 sensor. ONE+ adds specific notes for specific moments, such as meals, insulin doses, and sports activities. This system replaces traditional finger sticks and gives you a clear picture of how your daily choices affect your blood sugar levels.
CGM/AID pairing
All of these products are already relatively established in the diabetes field, but new applications are being brought to light thanks to a series of integrations between CGMs and automated insulin delivery systems announced over the past few months. I did. This integration gives diabetics more options in how they measure their blood sugar levels and administer insulin.
Notable updates include:
These diabetes technologies have not yet been approved, but may emerge
envector patch pump
Embecta, a spin-off of BD Diabetes, has developed a unique disposable pump for patients with type 2 diabetes. The company provided analysts with details about the configuration of its open-loop system earlier this year. A closed-loop version is also in development. This version incorporates algorithms that require Embecta to perform clinical research.
CEO Dev Kurdikar recently said: Drug delivery business news Pumps “will be a key part” of Envector’s strategy, he said.
The company announced in January that it had submitted its patch pump to the FDA for approval.
Modular Medical insulin pumps
In January, Modular Medical announced that it had completed its submission to the FDA for approval of its MODD1 insulin pump.
Modular Medical has designed the 90-day MODD1 with novel microfluidic technology that enables low-cost insulin infusion. The new intuitive design makes the product easy to use and prescribe.
The pump reservoir size is 300 units/3mL. Users can monitor pump operation with their mobile phone and no external controller is required. The pump uses the included disposable battery.
CEO Jeb Besser said the first questions from the FDA are expected during the quarter ending June 30, 2024. While a release this year may be a long way off, it could still happen in the near future.
PharmaSens patch pump
PharmaSens closed out 2023 by filing an application for FDA approval for the Niia Essential insulin patch pump system.
The first of PharmaSens’ three patch pumps, Niia Essential features a patient-centered design aimed at increasing ease of use. The company says it aims to address unmet needs in the diabetes management market.
PharmaSens has designed a basal bolus patch pump that combines the ease of use of an insulin pen with the benefits of a sophisticated pump. Featuring a 3 mL reservoir, it provides extended use and access to reimbursed patch pump therapy. According to PharmaSens, this design positions the Niia Essential as one of the most compact patch pumps on the market.
PharmaSens said it expects favorable FDA review and is already preparing to bring the drug to market once approval is obtained.
